Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: The MERENA observational cohort study

BMC Nephrology

Volumn 12, Issue 1, 2011, Pages

  Martínez Castelao, Alberto ^a   Górriz, José L ^b   Portolés, José M ^c   De Alvaro, Fernando ^d   Cases, Aleix ^e   Lũo, José ^f   Navarro González, Juan F ^g   Montes, Rafael ^h   De La Cruz Troca, Juan J ⁱ   Natarajan, Aparna ^j   Batlle, Daniel ^j  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

ⁱ UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^j NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM; HEMOGLOBIN; IRON; PARATHYROID HORMONE; PHOSPHORUS; PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART DISEASE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; MORBIDITY; OBSERVATIONAL STUDY; OUTPATIENT DEPARTMENT; PERIPHERAL VASCULAR DISEASE; PROSPECTIVE STUDY; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPAIN;

EID: 80053480053     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-12-53     Document Type: Article

References (31)

1. Prevalence of Chronic Kidney Disease in the United States. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS, JAMA 2007 298 17 2038 2047 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
2. Chronic Kidney Disease in the United States: A Public Policy Imperative. Rettig RA, Norris K, Nissenson AR, Clin J Am Soc Nephrol 2008 3 6 1902 1910 10.2215/CJN.02330508 18922986
3. Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. Ruggenenti P, Remuzzi G, Clin J Am Soc Nephrol 2007 2 1 146 150 17699399
4. Progress in retarding the progression of advanced chronic kidney disease: Grounds for optimism. Batlle D, Ramadugu P, Soler MJ, Kidney Int 70 S104 40 S44
5. Stabilization of glomerular filtration rate in advanced chronic kidney disease: a two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5. Serrano A, Huang J, Ghossein C, Nishi L, Gangavathi A, Madhan V, Ramadugu P, Ahya SN, Paparello J, Khosla N, Schlueter W, Batlle D, Adv Chronic Kidney Dis 2007 14 1 105 112 10.1053/j.ackd.2006.07.009 17200050 (Pubitemid 46014530)
6. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C, N Engl J Med 2004 351 13 1296 1305 10.1056/NEJMoa041031 15385656 (Pubitemid 39268908)
7. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH, Arch Intern Med 2004 164 6 659 663 10.1001/archinte.164.6.659 15037495 (Pubitemid 38392981)
8. Clinical practice. Stage IV chronic kidney disease. Abboud H, Henrich WL, N Engl J Med 2010 362 1 56 65 10.1056/NEJMcp0906797 20054047
9. CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. Weiner D, Krassilnikova M, Tighiouart H, Salem D, Levey A, Sarnak M, BMC Nephrology 2009 10 1 26 10.1186/1471-2369-10-26 19761597
10. Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study: Baseline results. Warnock DG, McClellan W, McClure LA, Newsome B, Campbell RC, Audhya P, Cushman M, Howard VJ, Howard G, Kidney Int 2005 68 4 1427 1431 10.1111/j.1523-1755.2005.00553.x 16164617 (Pubitemid 43169887)
11. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, Hypertension 2003 42 5 1050 1065 10.1161/01.HYP.0000102971.85504.7c 14604997 (Pubitemid 37413751)
12. Prevalence of chronic renal disease in Spain: Results of the EPIRCE study Nefrologia. Otero A, Gayoso P, Garcia F, de Francisco AL, on behalf of the EPIRCE Study Group, 2010 30 78 86
13. [Prevalence of kidney insufficiency in primary care population in Spain: EROCAP study]. de Francisco ALM, De la Cruz JJ, Cases A, de la Figuera M, Egocheaga MI, Gárriz JL, Llisterri JI, Marín R, Martínez Castelao A, Nefrologia 2007 27 3 300 312 17725449
14. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 2 Suppl 1 1 266 11904577
15. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. De Nicola L, Minutolo R, Chiodini P, Zoccali C, Castellino P, Donadio C, Strippoli M, Casino F, Giannattasio M, Petrarulo F, Virgilio M, Laraia E, Di Iorio BR, Savica V, Conte G, Kidney Int 2006 69 3 538 545 10.1038/sj.ki.5000085 16395261 (Pubitemid 43164447)
16. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, Townsend RR, Xie D, Cifelli D, Cohan J, Fink JC, Fischer MJ, Gadegbeku C, Hamm LL, Kusek JW, Landis JR, Narva A, Robinson N, Teal V, Feldman HI, Clin J Am Soc Nephrol 2009 4 8 1302 1311 10.2215/CJN.00070109 19541818
17. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. Hallan SI, Coresh J, Astor BC, Asberg A, Powe NR, Romundstad S, Hallan HA, Lydersen S, Holmen J, J Am Soc Nephrol 2006 17 8 2275 2284 10.1681/ASN.2005121273 16790511 (Pubitemid 44141918)
18. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, Ann Intern Med 2009 150 604 612 19414839
19. Revised European Best Practice Guidelines for the management of anemia in patients with chronic renal failure. Locatelli F, Aljama P, Bárány P, Canaud B, Carrera F, Eckardt KU, Hörl WH, Macdougal IC, Macleod A, Wiecek A, Cameron S, Nephrol Dial Transplant 2004 19 Suppl 2 1 47 14671027
20. KD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. McCullough PA, Li S, Jurkovitz CT, Stevens LA, Wang C, Collins AJ, Chen S, Norris KC, McFarlane SI, Johnson B, Shlipak MG, Obialo CI, Brown WW, Vassalotti JA, Whaley-Connell AT, Am J Kidney Dis 2008 51 4 Suppl 2 38 45 18359407
21. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005 45 4 Suppl 3 1 153 15806502
22. Intensive blood-pressure control in hypertensive chronic kidney disease. Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X, N Engl J Med 2010 363 10 918 929 10.1056/NEJMoa0910975 20818902
23. Debate: CON Position. People with Chronic Kidney Disease Should Have a Blood Pressure Lower than 130/80 mm Hg. Agarwal R, Am J Nephrol 2010 32 4 374 376 10.1159/000319637 20814194
24. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001 37 1 Suppl 1 182 238 11229970
25. Haemoglobin targets: we were wrong, time to move on. Strippoli GFM, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC, Lancet 2007 369 9559 346 350 10.1016/S0140-6736(07)60165-2 17276756 (Pubitemid 46188478)
26. Does TREAT give the boot to ESAs in the treatment of CKD anemia? Singh AK, J Am Soc Nephrol 2010 21 1 2 6 10.1681/ASN.2009111127 20035034
27. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks. Locatelli F, Gascán P, Oncologist 2009 14 Suppl 1 57 62 19762517
28. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. Pfeffer MA, Burdmann EA, Chen C, Cooper ME, de Zeeuw D, Eckardt K, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving H, Remuzzi G, Singh AK, Solomon SD, Toto R, N Engl J Med 2009 361 21 2019 2032 10.1056/NEJMoa0907845 19880844
29. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Craver L, Marco MP, Martínez I, Rue M, Borrs M, Martín ML, Sarrá F, Valdivielso JM, Fernández E, Nephrol Dial Transplant 2007 22 4 1171 1176 10.1093/ndt/gfl718 17205962 (Pubitemid 46523434)
30. A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, Hippensteel R, Pradhan RS, Palaparthy RV, Kavanaugh A, Melnick JZ, Williams LA, Batlle D, Am J Nephrol 2006 26 1 105 114 10.1159/000092033 16543714
31. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003 42 4 Suppl 3 1 201 14520607